SWISX
Price
$27.97
Change
+$0.03 (+0.11%)
Updated
Aug 26 closing price
Net Assets
11.99B
VTISX
Price
$162.08
Change
+$0.07 (+0.04%)
Updated
Aug 26 closing price
Net Assets
505.75B
Interact to see
Advertisement

SWISX vs VTISX

Header iconSWISX vs VTISX Comparison
Open Charts SWISX vs VTISXBanner chart's image
Schwab International Index
Price$27.97
Change+$0.03 (+0.11%)
VolumeN/A
Net Assets11.99B
Vanguard Total Intl Stock Idx Instl Sel
Price$162.08
Change+$0.07 (+0.04%)
VolumeN/A
Net Assets505.75B
SWISX vs VTISX Comparison Chart in %
Loading...
View a ticker or compare two or three
VS
SWISX vs. VTISX commentary
Aug 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SWISX is a Buy and VTISX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
VTISX has more cash in the bank: 506B vs. SWISX (12B). VTISX (2.87) and SWISX (2.80) have matching dividends . SWISX was incepted earlier than VTISX: SWISX (28 years) vs VTISX (9 years). SWISX (0.06) is less costly to investors than VTISX (0.05). SWISX is a more actively managed with annual turnover of: 7.00 vs. VTISX (3.00). SWISX has a lower initial minimum investment than VTISX: SWISX (0) vs VTISX (3000000000). SWISX (15.00) and VTISX (14.50) have marching annual gain over last year. SWISX return over 5 years is better than : 56.38 vs. VTISX (39.14).
SWISXVTISXSWISX / VTISX
Total Expense Ratio0.060.05128%
Annual Report Gross Expense Ratio0.060.05128%
Fund Existence28 years9 years-
Gain YTD23.57421.707109%
Front LoadN/AN/A-
Min. Initial Investment03000000000-
Min. Initial Investment IRAN/AN/A-
Net Assets12B506B2%
Annual Yield % from dividends2.802.8798%
Returns for 1 year15.0014.50103%
Returns for 3 years55.0941.62132%
Returns for 5 years56.3839.14144%
Returns for 10 years76.75N/A-
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
RAPP16.011.38
+9.43%
Rapport Therapeutics Inc.
GMAB24.540.23
+0.95%
Genmab A/S ADS
PAYO6.76-0.02
-0.29%
Payoneer Global
PMCB1.01-0.01
-1.42%
PharmaCyte Biotech
CSBR6.73-0.33
-4.67%
Champions Oncology